Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-09-19 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of temporarily idle raised funds by Qianyan Biopharmaceutical (Nanjing) Co., Ltd. for cash management. It includes specifics about the fundraising, investment projects, cash management purposes, limits, risk analysis, internal approvals, and the sponsor's verification opinion. The document references regulatory guidelines and approvals but does not contain financial statements or earnings data. It is a formal verification or audit-type report related to the use of raised funds, not an annual or interim financial report, earnings release, or capital update. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on the use of funds, including compliance with regulations and internal controls, without being a full annual report or earnings release. Q3 2023
2023-09-19 Chinese
前沿生物关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory approvals, investment limits, risk controls, and compliance with regulatory requirements. It references specific approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. The document does not contain financial statements or detailed financial results but rather describes a corporate financing activity related to the management of raised capital. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's fundraising capital usage and management activities.
2023-09-19 Chinese
前沿生物关于第三届监事会第九次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the ninth meeting of the third Supervisory Board of the company. It details the meeting's attendance, the agenda items discussed, and the voting results on the use of idle raised funds for temporary liquidity and cash management. The document does not contain financial statements or detailed financial data but rather reports on governance decisions and approvals related to fund usage. It also references other announcements published on the stock exchange website for more details. The document length is short (1527 characters), and it is clearly an announcement of meeting resolutions rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-19 Chinese
前沿生物关于归还前次暂时补充流动资金的闲置募集资金并继续使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use and return of idle raised funds temporarily supplementing working capital. It details the approval by the board and supervisory committee, references regulatory guidelines on the management and use of raised funds, and includes independent opinions and verification from the sponsor institution. The document does not contain financial statements or detailed financial results but focuses on the company's capital management activities related to raised funds. It is not a full financial report, audit report, or earnings release. The content fits the category of Capital/Financing Update (CAP), as it concerns updates on the company's fundraising and capital usage activities.
2023-09-19 Chinese
前沿生物独立董事关于第三届董事会第十次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on specific proposals related to the use of idle raised funds for temporary liquidity and cash management. It references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (825 characters) and focuses on governance and regulatory compliance matters related to fundraising usage. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of voting results.
2023-09-19 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年半年度持续督导跟踪报告" which translates to "2023 Semi-Annual Continuous Supervision Follow-up Report" issued by the sponsor (中信证券股份有限公司) for the company 前沿生物药业（南京）股份有限公司. It details the sponsor's ongoing supervision activities, compliance with regulatory requirements, risk factors, financial data for the first half of 2023, R&D progress, use of raised funds, and shareholding information. The document contains substantive financial data and analysis for the half-year period ending June 30, 2023, including income, profit, cash flow, and financial ratios. It is not a full annual report (10-K), but a comprehensive interim report covering a period shorter than a full fiscal year with detailed financial and operational information. It is not merely an announcement or certification but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-09-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.